AttackMS
@attackms_trial
Testing the safety and efficacy of natalizumab (Tysabri) very early in MS. Evidence suggests this will give MS patients a better long-term outcome.
ID: 1666476262112600066
07-06-2023 16:05:01
10 Tweet
129 Takipรงi
219 Takip Edilen
Fantastic new tool to help MS patients navigate life during this time of long waits for NHS services, developed by a member of the #AttackMS team Andrea Stennett PhD ๐๐๐ AttackMS participants have fast access to treatment - we hope everyone will one day soon!